Background: Homozygous cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss is one of the parameters that support the designation of meningiomas as Central Nervous System (CNS) WHO grade 3 tumors. Evaluation of CDKN2A/B by sequencing or Fluorescence in situ hybridization (FISH) is costly and not always readily accessible. An immunohistochemistry (IHC)-based marker for the evaluation of CDKN2A/B loss would provide faster results at a lower cost.
Methods: This retrospective study included patients diagnosed with meningioma at our institution between 2016 and 2019. Archival tumor tissue was used for analysis. MTAP immunohistochemistry (IHC) was performed at various dilutions (1:1200, 1:400, 1:200, 1:100) using two different antibodies, and p16 IHC was conducted simultaneously. These analyses were carried out at two different institutions. To determine the sensitivity and specificity of MTAP and p16 as surrogate markers for CDKN2A/B loss, FISH was utilized as the gold standard.
Results: Overall, 46/49 tumors showed strong MTAP staining (94%) at institution 1, and 44/49 (90%) showed either faint positive or positive results at institution 2. One grade 3 meningioma that demonstrated homozygous loss by FISH also showed loss of MTAP expression by IHC. One grade 2 meningioma showed regional loss by FISH and variable MTAP expression under different IHC conditions. MTAP expression evaluation was superior at a dilution of 1:100 with the Abnova Anti-MTAP Monoclonal antibody.
Conclusions: P16 expression was variable and did not correlate with either MTAP expression or FISH results. MTAP IHC is a promising surrogate marker for the evaluation of status in meningiomas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11476088 | PMC |
| http://dx.doi.org/10.3390/cancers16193299 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interferon-ε loss is elusive 9p21 link to immune-cold tumors, resistant to immune-checkpoint therapy and endogenous CXCL9/10 induction.
J Thorac Oncol
December 2024
Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA; Department of Medicine, University of California San Diego, La Jolla, CA 92037, USA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Introduction: Copy-number (CN) loss of chromosome 9p, or parts thereof, impair immune response and confer ICT resistance by direct elimination of immune-regulatory genes on this arm, notably IFNγ genes at 9p24.1, and type-I interferon (IFN-I) genes at 9p21.3.
View Article and Find Full Text PDFFatal Spitz Melanoma With MAD1L1::BRAF Fusion: A Case Report and Literature Review.
J Cutan Pathol
December 2024
Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Sunto, Japan.
Spitz melanoma is extremely rare, and only a few cases of distant metastases have been reported. Herein, we describe a case of Spitz melanoma with multiple distant metastases. A 37-year-old woman presented with a 5.
View Article and Find Full Text PDFMolecular profile of adult primary leptomeningeal gliomatosis aligns with glioblastoma, IDH-wildtype.
Brain Pathol
December 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Article Synopsis
- Adult primary leptomeningeal gliomatosis (PLG) is a rare and aggressive disease that affects the meninges with glial tumor infiltration but no obvious brain mass, and it has not been thoroughly studied at the molecular level.
- In a study of six PLG patients, all showed leptomeningeal enhancement; most were diagnosed via biopsy revealing astrocytic gliomas with notable genetic mutations, including IDH-wildtype and TERT promoter alterations, which indicated similarities to adult-type glioblastoma.
- All patients unfortunately died from the disease, with a median survival of just 24 days after diagnosis, although one case with early intervention survived significantly longer, suggesting that early detection and treatment may
Canonical Amplifications and CDKN2A/B Loss Refine IDH1/2-mutant Astrocytoma Prognosis.
Neuro Oncol
November 2024
Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts.
Article Synopsis
- Molecular features, particularly CDKN2A/B loss, impact survival outcomes in IDH1/2-mutant astrocytomas, with grade 2/3 tumors showing varied survival based on molecular characteristics.
- In a study of 998 patients, those with intact CDKN2A/B and no focal amplifications had the longest survival, while variations in CDKN2A/B status correlated with poorer outcomes, particularly in grade 4 tumors.
- The research highlights the potential for improved prognostic predictions in IDHmut-astrocytomas by integrating molecular data with histological grading, revealing distinct profiles linked to survival outcomes.
Patient-derived glioma organoids real time identification of IDH mutation, 1p/19q-codeletion and CDKN2A/B homozygous deletion with differential ion mobility spectrometry.
J Neurooncol
February 2025
Department of Neurosurgery and Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland.
Purpose: Extent of brain tumor resection continues to be one of the central decisions taken during standard of care in glioma patients. Here, we aimed to evaluate the most essential molecular factors, such as IDH (isocitrate dehydrogenase) mutation in gliomas classification with patient-derived glioma organoids (PGOs) using differential mobility spectrometry (DMS).
Methods: we prospectively recruited 12 glioma patients, 6 IDH-mutated and 6 IDH wild-type tumors, from which PGOs were generated ex-vivo.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!